Comparison · NCT02544750-sae
GWP42003-P (Double-blind Phase) vs Placebo (Double-blind Phase): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GWP42003-P (Double-blind Phase) vs Placebo (Double-blind Phase): serious adverse events. Trial comparisons, record NCT02544750-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02544750-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.24 | 0.158 | 0.348 | wilson | |
| Risk in group 2 | 0.306 | 0.232 | 0.392 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0665 | -0.186 | 0.0645 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.783 | 0.484 | 1.27 | log | |
| Odds ratio, group 1 over group 2 | 0.715 | 0.372 | 1.37 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on GWP42003-P (Double-blind Phase) than on Placebo (Double-blind Phase) | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GWP42003-P (Double-blind Phase) | Participants who had received GWP42003-P during the double-blind phase and then GWP42003-P in the OLE phase. | 18 | 75 | EG001 |
| Group 2 | Placebo (Double-blind Phase) | Participants who had received placebo during double-blind phase and then GWP42003-P in the OLE phase. | 38 | 124 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment-emergent adverse events (TEAEs) were collected from OLE Day 1 up to 4 years.
Source ClinicalTrials.gov
Trial
- Title
- An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- NCT number
- NCT02544750
- Phases
- PHASE3
- Conditions
- Tuberous Sclerosis Complex, Seizures
- Interventions
- GWP42003-P
- Lead sponsor
- Jazz Pharmaceuticals
- Results first posted
- 2022-07-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02544750?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02544750-sae